Loading quotes...

Forecast

Buy	1
Hold	0
Sell	0

News Go to news feed

Zomedica reports record revenue growth in Q1 2026

Zomedica posted revenue of $8.8 million in Q1 2026 (up 35% year over year), marking the 21st consecutive quarter of revenue growth. The diagnostics segment was a major contributor, growing 73%, while adjusted non‑GAAP EBITDA loss improved to $2.4 million (vs. $5.7 million). The company held $47.5 million in cash and plans new TRUFORMA assays for Q3/Q4 2026 and PIMS integration by September 2026; the stock rose 17.9%. » More on de.investing.com
Zomedica partners with Boehringer Ingelheim on horse diagnostics

Zomedica is integrating its TRUFORMA diagnostics system into Boehringer Ingelheim’s idPPID program to improve detection and monitoring of PPID in horses. The partnership allows veterinarians to run rapid on‑site tests for equine endogenous ACTH and insulin; Boehringer will reimburse costs for diagnostic tests and provide TRUFORMA devices to clinics free of charge. The agreement expands Zomedica’s installed base, enables reorders of cartridges (including cortisol and progesterone), and is intended to complement Boehringer’s test offerings. Zomedica reported $32 million in revenue in 2025, about $53 million in cash, and 17% revenue growth; however, analysts do not expect profitability in the current year. » More on de.investing.com
Zomedica boosts revenue 16% despite missed EPS — stock climbs 17.9%

Zomedica reported a 16% revenue increase to $8.1 million in Q3 2025, while earnings per share of -$0.01 missed expectations. The company cut operating costs by $2.5 million, grew international sales by 20% and reduced cash burn by 25% compared with 2024. Cash on hand was $54.4 million, and Zomedica is targeting cash-flow break-even by 2027 as well as the market launch of new products. After the results, the stock rose 17.9%, reflecting investor confidence in operational efficiency and growth potential. » More on de.investing.com

Financials

In the last quarter, ZOMEDICA CORP. had revenue of €8.33m and net profit of -€3.3m

(EUR)	June 2026	YoY
Revenue	8.33m	6.61%
Gross profit	5.29m	13.38%
Net profit	-3.3m	14.56%
EBITDA	-3.58m	18.72%

Fundamentals

Metric	Value
Market capitalization	€85.32m
Number of shares	979.95m
52-week high/low	€0.17 - €0.0135
Dividends	No
Beta	1.16
P/E ratio	-12.80
PEG ratio	-0.34
P/B ratio	0.89
P/S ratio	5.01

Company profile

Zomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. The company engages in the development and commercialization of TRUFORMA platform, which offers point-of-care diagnostic products for disease states in dogs and cats; and PulseVet, provides for treatment of various musculoskeletal issues, such as broken bones, tendonitis, and torn ligaments in horses and small animals. It has collaboration agreements with Celsee, Inc. for the development and commercialization of liquid biopsy assays and related consumables for the detection of cancer in companion animals; and Seraph Biosciences, Inc. for development and markets a novel pathogen detection system. The company was formerly known as Zomedica Pharmaceuticals Corp. and changed its name to Zomedica Corp. in October 2020. Zomedica Corp. was founded in 2015 and is headquartered in Ann Arbor, Michigan.